Immunogenicity and protective efficacy of the E. coli-expressed domain III of Japanese encephalitis virus envelope protein in mice

Medical Microbiology and Immunology

Volumn 196, Issue 4, 2007, Pages 227-231

  Alka, ^a   Bharati, Kaushik ^a   Malik, Y P S ^a,b   Vrati, Sudhanshu ^a  

^a JAWAHARLAL NEHRU UNIVERSITY   (India)

^b Biotechnology Centre   (India)

Author keywords

Adjuvant; Enzyme linked immunosorbent assay; Neutralization

Indexed keywords

ALUMINUM HYDROXIDE; BACTERIUM LYSATE; ENVELOPE PROTEIN DOMAIN 3; FREUND ADJUVANT; HISTIDINE; HYBRID PROTEIN; MALTOSE BINDING PROTEIN; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

AMINO TERMINAL SEQUENCE; ANTIBODY TITER; ARTICLE; CELL INCLUSION; CONTROLLED STUDY; ESCHERICHIA COLI; IMMUNIZATION; IMMUNOGENICITY; JAPANESE ENCEPHALITIS VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PURIFICATION; PROTEIN SYNTHESIS; SOLUBILITY; VIRUS INFECTION;

ANIMALS; ANTIBODIES, VIRAL; ENCEPHALITIS VIRUS, JAPANESE; ESCHERICHIA COLI; JAPANESE ENCEPHALITIS VACCINES; MANNOSE-BINDING LECTIN; MICE; MICE, INBRED BALB C; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS;

EID: 36148996839     PISSN: 03008584     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00430-007-0043-4     Document Type: Article

References (24)

1. Bharati K, Vrati S (2006) Japanese encephalitis: development of new candidate vaccines. Expert Rev Anti Infect Ther 4:313-324
2. Cecilia D, Gould EA (1991) Nucleotide changes responsible for loss of neuroinvasiveness in Japanese encephalitis virus neutralization-resistant mutants. Virology 181:70-77
3. Crill WD, Roehrig JT (2001) Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol 75:7769-7773
4. Halstead SB, Jacobson J (2003) Japanese encephalitis. Adv Virus Res 61:103-138
5. Kapust RB, Waugh DS (1999) Escherichia coli maltose-binding protein is uncommonly effective at promoting the solubility of polypeptides to which it is fused. Protein Sci 8:1668-1674
6. Kaur R, Sachdeva G, Vrati S (2002) Plasmid DNA immunization against Japanese encephalitis virus: immunogenicity of membrane-anchored and secretory envelope protein. J Infect Dis 185:1-12
7. Kolaskar AS, Kulkarni-Kale U (1999) Prediction of three-dimensional structure and mapping of conformational epitopes of envelope glycoprotein of Japanese encephalitis virus. Virology 261:31-42
8. Lin CW, Wu SC (2003) A functional epitope determinant on domain III of the Japanese encephalitis virus envelope protein interacted with neutralizing-antibody combining sites. J Virol 77:2600-2606
9. Lindenbach BD, Rice CM (2001) Flaviviridae: the viruses and their replication. In: Knipe DM, Howley PM (eds) Fields virology, 4th edn. Lippincott Williams & Wilkins, Philadelphia, pp 991-1041
10. Mason PW, Dalrymple JM, Gentry MK, McCown JM, Hoke CH, Burke DS, Fournier MJ, Mason TL (1989) Molecular characterization of a neutralizing domain of the Japanese encephalitis virus structural glycoprotein. J Gen Virol 70(Pt 8):2037-2049
11. Plesner AM (2003) Allergic reactions to Japanese encephalitis vaccine. Immunol Allergy Clin North Am 23:665-697
12. Poland JD, Cropp CB, Craven RB, Monath TP (1990) Evaluation of the potency and safety of inactivated Japanese encephalitis vaccine in US inhabitants. J Infect Dis 161:878-882
13. Reed LJ, Muench H (1938) A simple method of estimating 50 per cent end-points. Am J Hyg 27:493-497
14. Rey FA, Heinz FX, Mandl C, Kunz C, Harrison SC (1995) The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature 375:291-298
15. Saini M, Vrati S (2003) A Japanese encephalitis virus peptide present on Johnson grass mosaic virus-like particles induces virus-neutralizing antibodies and protects mice against lethal challenge. J Virol 77:3487-3494
16. Seif SA, Morita K, Igarashi A (1996) A 27 amino acid coding region of JE virus E protein expressed in E. coli as fusion protein with glutathione-S- transferase elicit neutralizing antibody in mice. Virus Res 43:91-96
17. Seif SA, Morita K, Matsuo S, Hasebe F, Igarashi A (1995) Finer mapping of neutralizing epitope(s) on the C-terminal of Japanese encephalitis virus E-protein expressed in recombinant Escherichia coli system. Vaccine 13:1515-1521
18. Simmons M, Nelson WM, Wu SJ, Hayes CG (1998) Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice. Am J Trop Med Hyg 58:655-662
19. Singh SM, Panda AK (2005) Solubilization and refolding of bacterial inclusion body proteins. J Biosci Bioeng 99:303-310
20. Sumiyoshi H, Mori C, Fuke I, Morita K, Kuhara S, Kondou J, Kikuchi Y, Nagamatu H, Igarashi A (1987) Complete nucleotide sequence of the Japanese encephalitis virus genome RNA. Virology 161:497-510
21. Vrati S, Agarwal V, Malik P, Wani SA, Saini M (1999) Molecular characterization of an Indian isolate of Japanese encephalitis virus that shows an extended lag phase during growth. J Gen Virol 80:1665-1671
22. World Health Organization (1998) Japanese encephalitis vaccines. Wkly Epidemiol Rec 73:337-344
23. Wu SC, Lian WC, Hsu LC, Liau MY (1997) Japanese encephalitis virus antigenic variants with characteristic differences in neutralization resistance and mouse virulence. Virus Res 51:173-181
24. Wu SC, Yu CH, Lin CW, Chu IM (2003) The domain III fragment of Japanese encephalitis virus envelope protein: mouse immunogenicity and liposome adjuvanticity. Vaccine 21:2516-2522